EGFR and prostate cancer: An extensive in-silico investigation into rutin compounds as potential inhibitors of prostate cancer signaling pathways revealed that the AKT, EGFR, and ERK signaling pathways were targeted by rutin derivatives, which could prevent prostate cancer from spreading [134].